NKTR Nektar Therapeutics

• None no insider bought on the open market
• None no sales outside a trading plan
• $2.1M sold by 2 insiders under 10b5-1 plans

1. Insider
   Trade
   Value
   Traded, filed
2. Jonathan Zalevsky Chief R&D Officer
   Planned sale
   $398K 5,681 shares at $70.00 37% of stake
   Traded Jun 30 Filed Jul 2
   ↗
3. Howard W Robin CEO
   Planned sale
   $1.2M 20,000 shares at $60.75 27% of stake
   Traded Jun 16–17 Filed Jun 18
   ↗
4. Jonathan Zalevsky Chief R&D Officer
   Planned sale
   $336K 5,538 shares at $60.71 26% of stake
   Traded Jun 15 Filed Jun 17
   ↗
5. Jonathan Zalevsky Chief R&D Officer
   Planned sale
   $138K 3,867 shares at $35.67 15% of stake
   Traded Jan 20 Filed Jan 22
   ↗

Also filed in the last 12 months, not counted as buying or selling: 10 stock grants and 9 sales to cover taxes.